Objective: To retrospectively analyze the clinical efficacy and safety of linperlisib combined with azacitidine in patients with lymphoma.Methods: We collected data from 14 lymphoma patients treated with the linperlisib plus azacitidine regimen at our hospital. There were 7 male and 7 female patients, with a median age of 60 years (range: 18 to 75). Three patients (21.4%) were treatment-naïve, while 11 patients (78.6%) had relapsed/refractory disease. Two patients had received prior stem cell transplantation. Disease types included: Angioimmunoblastic T-cell lymphoma (AITL, n=9), Anaplastic large cell lymphoma (ALCL, n=4), Peripheral T-cell lymphoma (PTCL, n=1).Results: All 14 patients received at least 2 treatment cycles. Eight patients (57.1%) achieved a complete response (CR), and six patients (42.9%) achieved a partial response (PR), resulting in an overall response rate (ORR) of 100%. Observed adverse events included: anemia (n=12, 85.7%), pneumonia (n=10, 71.4%), thrombocytopenia (n=6, 42.9%), febrile neutropenia (n=6, 42.9%), liver function impairment (n=4, 28.6%), nausea/vomiting (n=2, 14.3%), diarrhea (n=1, 7.1%), and hypersensitivity (n=1, 7.1%). Conclusion: The combination of linperlisib and azacitidine demonstrated promising efficacy and a manageable safety profile in patients with lymphoma.

This content is only available as a PDF.
2025
Sign in via your Institution